Voyager Therapeutics (VYGR) pipeline and stated timing

Name in SEC filings: Voyager Therapeutics, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
VY7523	/data readout	Stage not stated	2026	8-K · Aug 6, 2026

Source: ORION, orionbiotechai.com/company/VYGR, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/VYGR

Nearest upcoming stated timing: VY7523 · Topline/data readout · Q4 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

VY7523

Matched

Topline/data readoutQ4 2026

Stage: Not stated

Public float: $144,200,000 · as of Jun 30, 2025 · SEC filing

Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).

8-K · Filed Aug 6, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001640266-26-000007

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
VY7523Clinical results	Q4 2026 “Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).” Filed Aug 6, 2026 · EX-99.1	Still within period As of Oct 19, 2026
VY7523Clinical results	H2 2026 “Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in H2 2026 from the ongoing multiple ascending dose (MAD) clinical trial in AD patients.” Filed May 7, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
VY7523Clinical results	second half of 2026 “Enrollment in this MAD clinical trial was completed in the fourth quarter of 2025, and we expect initial tau positron emission tomography imaging efficacy data in the second half of 2026.” Filed May 7, 2026 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
VY7523Clinical results	second half of 2026 “We expect initial tau positron emission tomography, or PET, imaging data in the second half of 2026.” Filed Mar 9, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
VY7523Clinical results	second half of 2026 “VY7523 is currently in a Phase 1, multiple ascending dose, or MAD, clinical trial in early AD patients, from which we expect initial tau positron emission tomography, or PET, imaging data in the second half of 2026.” Filed Mar 11, 2025 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
VY7523Clinical results	second half of 2026 “Initial tau PET imaging data are expected in the second half of 2026.” Filed Mar 11, 2025 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
VY7523Clinical results	second half of 2026 “generate initial data for slowing the spread of pathological tau via tau positron emission tomography, or PET, imaging in the second half of 2026.” Filed Nov 12, 2024 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch VYGR

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for VYGR. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See VYGR in the calendar · Review labels and methodology